Inclusion Criteria:

          -  Patients with non-resectable, non-ablatable liver metastases from colorectal
             adenocarcinoma.

          -  Male or female 18 years or above.

          -  Primary tumour removed with an R0 resection, and histologically verified
             adenocarcinoma from colon or rectum

          -  Liver metastases measurable by MRI or CT according to RECIST version 1.1 Imaging
             within 4 weeks prior to inclusion.

          -  No signs of extrahepatic metastatic disease or local recurrence according to MRI and
             CT of thorax/abdomen and whole body Positron-emission tomography (PET)/ computed
             tomography (CT) scan.

          -  A colonoscopy performed within the last 12 months in order to exclude multifocal
             colorectal cancer (CRC) tumours.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Satisfactory blood tests: Hb ≥ 90 g/L (transfusions are permitted to achieve baseline
             hemoglobin level), White blood cell Count (WBC) >3,0x109/L, Absolute neutrophil count
             (ANC) ≥ 1.5 × 10^9/L, platelet Count (PLT) >75, Bilirubin<2 x upper normal level,
             Aspartate aminotransferase (ASAT), Alanine aminotransferase (ALAT)<5 x upper normal
             level, Calculated Creatinine clearance ≥ 50 mL/min(MDRD).

          -  Received at least 2 months of chemotherapy with no signs of progressive disease
             according to RECIST-criteria at the last evaluation before randomization.

          -  One year or more from the initial CRC diagnosis to the date of inclusion in the study

          -  Patient accepted for transplantation by a national study board

          -  Signed and dated written informed consent before the start of specific protocol
             procedures.

        Exclusion Criteria:

          -  Evidence of extrahepatic disease by PET-CT or CT-thorax/abdomen.

          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a
             negative pregnancy test performed within seven days prior to the start of study.

          -  Weight loss >10% the last 6 months

          -  Other malignancies within the last 5 years, except CRC and low risk tumours such as
             basaliomas.

             * Liver metastases larger than 10 cm.

          -  Pathological lymphatic nodes in the abdomen. If a patient has pathological lymphatic
             nodules in the hepatoduodenal ligament, a staging operation with histo-pathological
             examination from the nodules with no signs of tumour cell involvement has to be
             performed before inclusion.

          -  BRAF (a gene that encodes a protein called b-raf) mutation in primary tumour

          -  microsatellite instability (MSI-H) in primary tumour

          -  Previous organ transplantation